Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126506491 | 12650649 | 1 | I | 2016 | 20160811 | 20160815 | 20160815 | EXP | CH-ROCHE-1813327 | ROCHE | 0.00 | F | Y | 0.00000 | 20160815 | MD | CH | CH |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126506491 | 12650649 | 1 | PS | HERCEPTIN | TRASTUZUMAB | 1 | Intravenous (not otherwise specified) | U | N7104 | 103792 | 440 | MG | SOLUTION FOR INFUSION | ||||||
126506491 | 12650649 | 2 | SS | PERJETA | PERTUZUMAB | 1 | Intravenous (not otherwise specified) | U | H0122 | 125409 | 420 | MG | SOLUTION FOR INFUSION | ||||||
126506491 | 12650649 | 3 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | U | FD8507AA,FX2124 | 0 | 30 | MG | |||||||
126506491 | 12650649 | 4 | SS | PACLITAXEL. | PACLITAXEL | 1 | Unknown | U | FD8507AA,FX2124 | 0 | 100 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126506491 | 12650649 | 1 | HER-2 positive breast cancer |
126506491 | 12650649 | 2 | HER-2 positive breast cancer |
126506491 | 12650649 | 3 | HER-2 positive breast cancer |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126506491 | 12650649 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126506491 | 12650649 | Pneumonitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |